Penumbra, Inc. (PEN)
Price:
313.42 USD
( + 1.40 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Boston Scientific Corporation
VALUE SCORE:
8
2nd position
Stryker Corporation
VALUE SCORE:
9
The best
Abbott Laboratories
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
NEWS
Here's Why Penumbra (PEN) is a Strong Growth Stock
zacks.com
2025-12-15 10:45:23The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
First Trust Advisors LP Has $25.85 Million Position in Penumbra, Inc. $PEN
defenseworld.net
2025-12-11 05:08:54First Trust Advisors LP lifted its holdings in shares of Penumbra, Inc. (NYSE: PEN) by 4.0% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 100,723 shares of the company's stock after purchasing an additional 3,906 shares during the period. First Trust Advisors LP owned 0.26%
GMED or PEN: Which Is the Better Value Stock Right Now?
zacks.com
2025-12-03 12:41:08Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
seekingalpha.com
2025-12-03 12:33:37Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
American Century Companies Inc. Has $18.64 Million Holdings in Penumbra, Inc. $PEN
defenseworld.net
2025-12-03 03:18:52American Century Companies Inc. grew its holdings in Penumbra, Inc. (NYSE: PEN) by 202.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 72,651 shares of the company's stock after purchasing an additional 48,614 shares during the period. American Century Companies Inc.
Here's Why Penumbra (PEN) is a Strong Growth Stock
zacks.com
2025-11-27 10:46:13Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
17 Capital Partners LLC Has $990,000 Position in Penumbra, Inc. $PEN
defenseworld.net
2025-11-20 04:04:5417 Capital Partners LLC increased its position in shares of Penumbra, Inc. (NYSE: PEN) by 117.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,856 shares of the company's stock after acquiring an additional 2,085 shares during the period. 17 Capital
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
prnewswire.com
2025-11-19 16:30:00ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
zacks.com
2025-11-18 10:50:28The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
zacks.com
2025-11-11 08:56:05PEN's Q3 results impress with double-digit sales growth, margin expansion and a strong 20% stock surge after its earnings beat.
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
zacks.com
2025-11-10 10:45:51Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Spire Wealth Management Invests $91,000 in Penumbra, Inc. $PEN
defenseworld.net
2025-11-06 03:32:52Spire Wealth Management acquired a new stake in shares of Penumbra, Inc. (NYSE: PEN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 354 shares of the company's stock, valued at approximately $91,000. Several other institutional investors and hedge
Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-05 19:31:10Penumbra, Inc. ( PEN ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Cecilia Furlong Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President Maggie Yuen - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Vijay Kumar - Evercore Inc. Brandon Vazquez - William Blair & Company L.L.C., Research Division William Plovanic - Canaccord Genuity Corp., Research Division Michael Sarcone - Jefferies LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Presentation Operator Ladies and gentlemen, good afternoon.
Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-11-05 19:31:05Although the revenue and EPS for Penumbra (PEN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Penumbra (PEN) Q3 Earnings and Revenues Beat Estimates
zacks.com
2025-11-05 19:01:24Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to earnings of $0.85 per share a year ago.
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
prnewswire.com
2025-11-05 16:05:00ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.
No data to display
Here's Why Penumbra (PEN) is a Strong Growth Stock
zacks.com
2025-12-15 10:45:23The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
First Trust Advisors LP Has $25.85 Million Position in Penumbra, Inc. $PEN
defenseworld.net
2025-12-11 05:08:54First Trust Advisors LP lifted its holdings in shares of Penumbra, Inc. (NYSE: PEN) by 4.0% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 100,723 shares of the company's stock after purchasing an additional 3,906 shares during the period. First Trust Advisors LP owned 0.26%
GMED or PEN: Which Is the Better Value Stock Right Now?
zacks.com
2025-12-03 12:41:08Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
seekingalpha.com
2025-12-03 12:33:37Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
American Century Companies Inc. Has $18.64 Million Holdings in Penumbra, Inc. $PEN
defenseworld.net
2025-12-03 03:18:52American Century Companies Inc. grew its holdings in Penumbra, Inc. (NYSE: PEN) by 202.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 72,651 shares of the company's stock after purchasing an additional 48,614 shares during the period. American Century Companies Inc.
Here's Why Penumbra (PEN) is a Strong Growth Stock
zacks.com
2025-11-27 10:46:13Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
17 Capital Partners LLC Has $990,000 Position in Penumbra, Inc. $PEN
defenseworld.net
2025-11-20 04:04:5417 Capital Partners LLC increased its position in shares of Penumbra, Inc. (NYSE: PEN) by 117.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,856 shares of the company's stock after acquiring an additional 2,085 shares during the period. 17 Capital
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
prnewswire.com
2025-11-19 16:30:00ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
zacks.com
2025-11-18 10:50:28The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
zacks.com
2025-11-11 08:56:05PEN's Q3 results impress with double-digit sales growth, margin expansion and a strong 20% stock surge after its earnings beat.
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
zacks.com
2025-11-10 10:45:51Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Spire Wealth Management Invests $91,000 in Penumbra, Inc. $PEN
defenseworld.net
2025-11-06 03:32:52Spire Wealth Management acquired a new stake in shares of Penumbra, Inc. (NYSE: PEN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 354 shares of the company's stock, valued at approximately $91,000. Several other institutional investors and hedge
Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-05 19:31:10Penumbra, Inc. ( PEN ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Cecilia Furlong Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President Maggie Yuen - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Vijay Kumar - Evercore Inc. Brandon Vazquez - William Blair & Company L.L.C., Research Division William Plovanic - Canaccord Genuity Corp., Research Division Michael Sarcone - Jefferies LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Presentation Operator Ladies and gentlemen, good afternoon.
Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-11-05 19:31:05Although the revenue and EPS for Penumbra (PEN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Penumbra (PEN) Q3 Earnings and Revenues Beat Estimates
zacks.com
2025-11-05 19:01:24Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to earnings of $0.85 per share a year ago.
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
prnewswire.com
2025-11-05 16:05:00ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.